4D Molecular Therapeutics Inc (FDMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.55 Million) by net assets ($505.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FDMT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
4D Molecular Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
4D Molecular Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shoe Carnival Inc
NASDAQ:SCVL
|
0.034x |
|
Malaysia Smelting Corporation Bhd
KLSE:5916
|
0.133x |
|
Hey-Song Corp
TW:1234
|
-0.001x |
|
PLAYWAY SA
WAR:PLW
|
0.071x |
|
Varex Imaging Corp
NASDAQ:VREX
|
-0.003x |
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
-0.025x |
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NYSE:HQ
|
1.695x |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
0.098x |
Annual Cash Flow Conversion Efficiency for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of 4D Molecular Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 4D Molecular Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $505.66 Million | $-109.08 Million | -0.216x | +18.16% |
| 2024-12-31 | $510.61 Million | $-134.59 Million | -0.264x | -7.05% |
| 2023-12-31 | $307.83 Million | $-75.79 Million | -0.246x | +34.29% |
| 2022-12-31 | $231.34 Million | $-86.69 Million | -0.375x | -72.96% |
| 2021-12-31 | $319.11 Million | $-69.13 Million | -0.217x | -9.11% |
| 2020-12-31 | $256.39 Million | $-50.91 Million | -0.199x | -139.47% |
| 2019-12-31 | $-72.97 Million | $-36.71 Million | 0.503x | -14.60% |
| 2018-12-31 | $-27.59 Million | $-16.25 Million | 0.589x | +240.11% |
| 2017-12-31 | $-19.59 Million | $8.24 Million | -0.420x | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more